Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Prostatic Neoplasms 56Breast Neoplasms 49Lung Neoplasms 31Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 14Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Adenocarcinoma of Lung 7Sarcoma 6Esophageal Neoplasms 6Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Carcinoma, Ovarian Epithelial 4Triple Negative Breast Neoplasms 3Advanced Non-Small Cell Lung Cancer 3Adenocarcinoma, Bronchiolo-Alveolar 3Solid Tumor 2Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Inflammatory Breast Neoplasms 2Hormone Refractory Prostate Cancer 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

TroVax 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Prostatic Hyperplasia × Docetaxel × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡